Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyprexa Medicaid Cost Highlight Of OIG’s Mental Health Rx Spending Report

Executive Summary

The HHS Office of Inspector General's report on Medicaid spending for mental health drugs singles out Lilly's Zyprexa (olanzapine) as a particularly costly product for the program

You may also be interested in...



Lipitor Payments Under Medicaid Vary By 12% – IG

Some states paid as much as 12% more than the lowest paying states for identical units of Pfizer's Lipitor in fiscal year 2001, a report from the HHS Office of Inspector General concludes

Lipitor Payments Under Medicaid Vary By 12% – IG

Some states paid as much as 12% more than the lowest paying states for identical units of Pfizer's Lipitor in fiscal year 2001, a report from the HHS Office of Inspector General concludes

HHS IG To Study EPO, OxyContin Reimbursement In 2004 Reports

The HHS' Inspector General plans to study the "appropriateness" of epoetin alfa Medicare reimbursements for patients who have not been diagnosed with end stage renal disease

Related Content

UsernamePublicRestriction

Register

PS042409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel